NO20055307L - Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer - Google Patents

Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer

Info

Publication number
NO20055307L
NO20055307L NO20055307A NO20055307A NO20055307L NO 20055307 L NO20055307 L NO 20055307L NO 20055307 A NO20055307 A NO 20055307A NO 20055307 A NO20055307 A NO 20055307A NO 20055307 L NO20055307 L NO 20055307L
Authority
NO
Norway
Prior art keywords
treatment
radicals
compounds
diseases
cancer
Prior art date
Application number
NO20055307A
Other languages
English (en)
Other versions
NO20055307D0 (no
Inventor
Magnus Pfahl
Catherine Tachdjian
Hussien A Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Jianhua Guo
Mohamed Boudjelal
James W Zapf
Qing Chen
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of NO20055307D0 publication Critical patent/NO20055307D0/no
Publication of NO20055307L publication Critical patent/NO20055307L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår nye heterocykliske forbindelser med strukturen illustrert ved formel (I), hvor Ar1-radikalene er substituerte isokromanradikaler, Ar2-radikalene er aryl- eller heteroarylradikaler; og HAr er et 2,4-triazoiidindion-, 2-tiokso-tiazoiidin-4-on-, 2,4-imidazolidindion- eller 2-tiokso-imidazoiidin-4-onradikal. Forbindelsene med formel (I) kan ha biologisk aktivitet for fordelaktig regulering av karbohydrat-metabolismen, innbefattende serumglukosenivå, og lipidmetabolismen, og kan være anvendelige for behandling av hyperlipidemi og/eller hyperkolesterolemi, og dabetes type II. Forbindelsene med formel (I) kan også ha anvendbarhet ved behandling av sykdommer med ukontrollert proliferasjon, innbefattende kreft.
NO20055307A 2003-04-18 2005-11-10 Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer NO20055307L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46438803P 2003-04-18 2003-04-18
PCT/US2004/012284 WO2004093809A2 (en) 2003-04-18 2004-04-19 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Publications (2)

Publication Number Publication Date
NO20055307D0 NO20055307D0 (no) 2005-11-10
NO20055307L true NO20055307L (no) 2005-12-21

Family

ID=33310879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055307A NO20055307L (no) 2003-04-18 2005-11-10 Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer

Country Status (13)

Country Link
US (1) US20050038098A1 (no)
EP (1) EP1643993A2 (no)
JP (1) JP2006523724A (no)
KR (1) KR20060036896A (no)
CN (1) CN1774246A (no)
AU (1) AU2004232326A1 (no)
BR (1) BRPI0409501A (no)
CA (1) CA2522759A1 (no)
MX (1) MXPA05011242A (no)
NO (1) NO20055307L (no)
RU (1) RU2005135850A (no)
WO (1) WO2004093809A2 (no)
ZA (1) ZA200509355B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
US7265139B2 (en) * 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
TWI461423B (zh) * 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
CN102329192A (zh) * 2011-09-30 2012-01-25 山东天一化学股份有限公司 溴化苄的合成方法
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
CN105315223B (zh) * 2015-11-06 2017-08-25 河南大学 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用
US10231947B2 (en) * 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) * 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) * 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CN116693521A (zh) * 2023-05-10 2023-09-05 五邑大学 一种含色酮结构的噻唑烷二酮乙酯类化合物及其制备方法、药物组合物和应用
CN116693520A (zh) * 2023-05-10 2023-09-05 五邑大学 一种色酮噻唑二酮类化合物及其制备方法、药物组合物和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
JP2539504B2 (ja) * 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
ATE173728T1 (de) * 1991-07-22 1998-12-15 Pfizer Verfahren zur herstellung von (s)-4-(3-(5-methyl- 2-phenyl-4-oxazolyl)- 1-hydroxypropyl> brombenzol
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
AU692839B2 (en) * 1994-02-17 1998-06-18 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
NZ517993A (en) * 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US7265139B2 (en) * 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases

Also Published As

Publication number Publication date
AU2004232326A1 (en) 2004-11-04
JP2006523724A (ja) 2006-10-19
EP1643993A2 (en) 2006-04-12
BRPI0409501A (pt) 2006-04-18
CA2522759A1 (en) 2004-11-04
NO20055307D0 (no) 2005-11-10
WO2004093809A3 (en) 2005-04-21
ZA200509355B (en) 2007-03-28
CN1774246A (zh) 2006-05-17
RU2005135850A (ru) 2006-06-10
MXPA05011242A (es) 2006-07-06
KR20060036896A (ko) 2006-05-02
WO2004093809A2 (en) 2004-11-04
US20050038098A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20055307L (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
Koppireddi et al. Novel 2-(2, 4-dioxo-1, 3-thiazolidin-5-yl) acetamides as antioxidant and/or anti-inflammatory compounds
DE60316013T2 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
WO2003029223A1 (de) Substituierte n-(1, 4, 5, 6-tetrahydro-cyclopentapyrazol-3-yl)-derivate, und deren verwendung zur behandlung von krebs
DE19540027A1 (de) Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
EA200600122A1 (ru) Производные пиримидина для лечения патологического роста клеток
Raj et al. Synthesis of 1H-1, 2, 3-triazole linked β-lactam–isatin bi-functional hybrids and preliminary analysis of in vitro activity against the protozoal parasite Trichomonas vaginalis
NO20045679L (no) Nye fysiologik aktive substanser
Saroha et al. Novel 1, 2, 3-triazole-aurone hybrids as cathepsin B inhibitors: One-pot synthesis, anti-proliferative, and drug modeling studies
CN103664932B (zh) 一类吲哚接枝噻唑腙类衍生物及其制备方法和对癌细胞微管蛋白聚合的抑制作用
Bektaş et al. Design, synthesis, and characterization of some new benzimidazole derivatives and biological evaluation
EP0979823B1 (en) Novel amide compounds and drugs containing the same
EP0363796B1 (de) Heterocyclische substituierte Alkoxycumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
Wang et al. Design, synthesis, and in vitro evaluation of novel 3, 7‐disubstituted coumarin derivatives as potent anticancer agents
CA2355243C (en) Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives
CN111072634B (zh) 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
Dotsenko et al. Reaction of ethyl 4-aryl-6-bromomethyl-2-oxo-1, 2, 3, 4-tetrahydropyrimidine-5-carboxylates with N-methylmorpholinium 3-cyano-1, 4-dihydro-and 3-cyano-1, 4, 5, 6-tetrahydropyridine-2-thiolates
Matyk et al. Heterocyclic isosters of antimycobacterial salicylanilides
Singh et al. Benzoxazolyl linked benzylidene based rhodanine and analogs as novel antidiabetic agents: synthesis, molecular docking, and in vitro studies
AT510456B1 (de) Thiazolamin-derivate als zelldifferenzierungsbeschleuniger
DE69630799T2 (de) Pyrimidinderivate
Sondhi et al. Conventional and microwave-assisted synthesis of imidazole and guanidine derivatives and their biological evaluation
JP2010526045A (ja) Ｃｄｃ２５ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体
Vinaya et al. Synthesis and Antileukemic Activity of Novel 4‐(3‐(Piperidin‐4‐yl) Propyl) Piperidine Derivatives
Shivaprasad Shetty et al. Synthesis and α-amylase inhibition studies of some coumarin derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application